$0.41
0.02% today
Nasdaq, May 02, 06:54 pm CET
ISIN
US29446K1060
Symbol
EQ
Sector
Industry

Equillium, Inc. Stock price

$0.41
-0.09 18.62% 1M
-0.42 50.60% 6M
-0.34 45.20% YTD
-1.05 71.92% 1Y
-2.11 83.73% 3Y
-2.11 83.73% 5Y
-13.59 97.07% 10Y
Nasdaq, Closing price Thu, May 01 2025
-0.01 2.40%
ISIN
US29446K1060
Symbol
EQ
Sector
Industry

Key metrics

Market capitalization $14.64m
Enterprise Value $-7.56m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.40
EV/Sales (TTM) EV/Sales -0.18
P/S ratio (TTM) P/S ratio 0.36
P/B ratio (TTM) P/B ratio 0.76
Revenue growth (TTM) Revenue growth 13.89%
Revenue (TTM) Revenue $41.10m
EBIT (operating result TTM) EBIT $-8.27m
Free Cash Flow (TTM) Free Cash Flow $-19.11m
Cash position $22.58m
EPS (TTM) EPS $-0.23
P/E forward negative
Short interest 0.86%
Show more

Is Equillium, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,791 stocks worldwide.

Equillium, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Equillium, Inc. forecast:

2x Hold
100%

Analyst Opinions

2 Analysts have issued a Equillium, Inc. forecast:

Hold
100%

Financial data from Equillium, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
41 41
14% 14%
100%
- Direct Costs 0.14 0.14
8% 8%
0%
41 41
14% 14%
100%
- Selling and Administrative Expenses 12 12
12% 12%
28%
- Research and Development Expense 37 37
1% 1%
91%
-8.13 -8.13
44% 44%
-20%
- Depreciation and Amortization 0.14 0.14
8% 8%
0%
EBIT (Operating Income) EBIT -8.27 -8.27
43% 43%
-20%
Net Profit -8.07 -8.07
40% 40%
-20%

In millions USD.

Don't miss a Thing! We will send you all news about Equillium, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Equillium, Inc. Stock News

Neutral
Business Wire
one day ago
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced the advancement of a novel and potent aryl hydrocarbon receptor (AhR) modulator (EQ504), which was acquired through the acquisition of ...
Neutral
Business Wire
8 days ago
LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that the company has received feedback from its Type D meeting with the U.S. Food and Drug Administration (FDA) to discuss the regulatory pathw...
Neutral
Business Wire
about one month ago
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced topline data from the Phase 3 EQUATOR study evaluating itolizumab in first-line treatment of patients with acute graft-versus-hos...
More Equillium, Inc. News

Company Profile

Equillium, Inc. is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.

Head office United States
CEO Bruce Steel
Employees 35
Founded 2017
Website www.equilliumbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today